Eledon Pharmaceuticals (ELDN) Long-Term Deferred Tax (2013 - 2016)

Eledon Pharmaceuticals (ELDN) has 4 years of Long-Term Deferred Tax data on file, last reported at $65.6 million in Q4 2016.

• Quarterly Long-Term Deferred Tax rose 28.64% year-over-year to $65.6 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $65.6 million (up 28.64% YoY) and the FY2016 annual result came in at $65.6 million, up 28.64% from the prior year.
• Long-Term Deferred Tax advanced to $65.6 million in Q4 2016, from $51.0 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $65.6 million in Q4 2016 to a low of $24.4 million in Q4 2013.
• A 4-year average of $43.6 million and a median of $42.2 million in 2014 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2015 — Long-Term Deferred Tax surged 53.37% — and 2016, when it grew 28.64%.
• Tracing ELDN's Long-Term Deferred Tax over 4 years: stood at $24.4 million in 2013, then jumped by 36.35% to $33.3 million in 2014, then surged by 53.37% to $51.0 million in 2015, then rose by 28.64% to $65.6 million in 2016.
• The last three Long-Term Deferred Tax figures came in at $65.6 million (Q4 2016), $51.0 million (Q4 2015), and $33.3 million (Q4 2014), per Business Quant data.